Evidence map›Paper›PMID 36222931›Full record

ArticleJournal of molecular modeling2022

A molecular modeling on the potential application of beryllium oxide nanotube for delivery of hydroxyurea anticancer drug.

Mustafa M Kadhim, Ali Jihad, Safa K Hachim, Sallal A H Abdullaha, Taleeb Zedan Taban, Ahmed Mahdi Rheima

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mustafa M KadhimMedical Laboratory Techniques Department, Al-Farahidi University, Baghdad, 10022, Iraq. Mustafa_kut88@yahoo.com.
Ali JihadPharmacy Department, Al-Mustaqbal University College, Hilla, 51001, Iraq.
Safa K HachimCollege of Technical Engineering, The Islamic University, Najaf, Iraq.
Sallal A H AbdullahaDijlah University College, Baghdad, 10022, Iraq.
Taleeb Zedan TabanLaser and Optoelectronics Engineering Department, Kut University College, Kut, Wasit, Iraq.
Ahmed Mahdi RheimaDepartment of Chemistry, College of Science, Mustansiriyah University, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Within this work, we scrutinized the use of BeO nanotube (BeONT) as a nanocarrier for the anticancer drug hydroxyurea (HU) through density functional theory (DFT) calculations. We utilized the functional ꞷB97XD and the basis set 6-31G**. Based on a detailed surface analysis, HU was adsorbed on the surface of the nanotube through 4 different orientations. Also, no vibrational spectra exhibited imaginary frequencies, showing the minimum energy of the relaxed structures. The maximum adsorption energy and the minimum adsorption energy are in strong physical adsorption. The BeONT exhibited p-type semiconducting characteristics in all orientations since it received electronic charge from HU. The results demonstrate the possibility of using the BeONT as a promising carrier for HU drugs.

Indexed as

Antineoplastic AgentsNanotubesBerylliumHydroxyureaModels, MolecularAntineoplastic AgentsBerylliumberyllium oxideHydroxyureaAdsorption energyDensity functional theoryHydroxyureaPromising carrier

Identifiers

PMID36222931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.